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OBJECTIVE — To assess the association between antidepressant medicine use and risk of
developing diabetes during the Diabetes Prevention Program (DPP) and Diabetes Prevention
Program Outcomes Study (DPPOS).
RESEARCH DESIGN AND METHODS — DPP/DPPOS participants were assessed for
diabetes every 6 months and for antidepressant use every 3 months in DPP and every 6 months
in DPPOS for a median 10.0-year follow-up.
RESULTS — Controlled for factors associated with diabetes risk, continuous antidepressant
usecomparedwithnousewasassociatedwithdiabetesriskintheplacebo(adjustedhazardratio
2.34 [95% CI 1.32–4.15]) and lifestyle (2.48 [1.45–4.22]) arms, but not in the metformin arm
(0.55 [0.25–1.19]).
CONCLUSIONS — Continuous antidepressant use was signiﬁcantly associated with diabe-
tes risk in the placebo and lifestyle arms. Measured confounders and mediators did not account
for this association, which could represent a drug effect or reﬂect differences not assessed in this
study between antidepressant users and nonusers.
Diabetes Care 33:2549–2551, 2010
O
ur earlier report from the Diabetes
Prevention Program (DPP) (1) was
the ﬁrst to examine antidepressant
medicine (ADM)-related diabetes risk in
an overweight population with elevated
fasting glucose and impaired glucose tol-
erance. We found in the placebo and life-
style arms that when other factors
associatedwithdiabetesrisk(age,sex,ed-
ucation, fasting plasma glucose at base-
line, weight at baseline, weight change
during the study, and depression symp-
toms at baseline and during the study)
were controlled, baseline ADM use and
continuous ADM use during the study
(compared with no use) were associated
with signiﬁcantly increased diabetes risk;
in the lifestyle arm, intermittent ADM use
during the study was also associated with
increased diabetes risk. Among met-
formin arm participants, ADM use was
not associated with developing diabetes.
The present study extends the dura-
tion of follow-up in our previous report
by including 7 years of the Diabetes
Prevention Program Outcomes Study
(DPPOS) and providing a median 10.0-
year (interquartile range 9.0–10.5) fol-
low-up since randomization to the DPP.
RESEARCH DESIGN AND
METHODS — Participants (N  3,234)
athighriskfordevelopingtype2diabetes
were randomized to the DPP between
1996 and 1999. Characteristics of the
study population are reported else-
where (1).
In July 2001, masked DPP treatment
was discontinued after it was established
that lifestyle intervention reduced inci-
dence of diabetes by 58% and metformin
by 31% compared with placebo (2).
All 3,150 surviving DPP participants
who had not withdrawn consent were el-
igible for the DPPOS, and 2,665 enrolled.
Institutional review boards approved all
DPP and DPPOS protocols and informed
consent procedures. Participants signed
written consent forms after discussion of
all aspects of the studies with study
staff (3).
DPP/DPPOS participants brought all
prescription medicines, including ADMs,
to clinic visits. Study staff identiﬁed all
ADMs by generic name, brand name, or
both.
Diabetes was diagnosed based on an
annual oral glucose tolerance test or a
semiannual fasting plasma glucose test. A
conﬁrmation test was required, usually
within 6 weeks (1). Fasting insulin was
measured at annual visits with the oral
glucose tolerance test (2).
Statistical analysis
ADM use was reported quarterly during
the DPP and every 6 months during the
DPPOS. Cox proportional hazard models
●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●
Fromthe
1DepartmentofMedicine,TheJohnsHopkinsUniversitySchoolofMedicine,Baltimore,Maryland;
the
2Department of Pediatrics, The Johns Hopkins University School of Medicine, Baltimore, Maryland;
the
3Biostatistics Center, The George Washington University, Rockville, Maryland; the
4Department of
Sociology, Loyola University of Maryland, Baltimore, Maryland; the
5Department of Medicine, Indiana
University School of Medicine, Indianapolis, Indiana; the
6Department of Family Medicine, University of
Colorado Denver School of Medicine, Denver, Colorado; the
7Institute for Health Research, Kaiser Per-
manente, Denver, Colorado; the
8Department of Family and Preventative Medicine, University of Cali-
fornia, San Diego, La Jolla, California; and the
9National Institute of Diabetes and Digestive and Kidney
Diseases, Phoenix, Arizona.
Corresponding author: Richard R. Rubin, dppmail@biostat.bsc.gwu.edu.
Received1June2010andaccepted21August2010.Publishedaheadofprintathttp://care.diabetesjournals.
orgon30August2010.DOI:10.2337/dc10-1033.Clinicaltrialreg.no.NCT00038727,clinicaltrials.gov.
* A complete list of the members of the DPP/DPPOS research group can be found in an online appendix at
http://care.diabetesjournals.org/cgi/content/full/dc10-1033/DC1.
The opinions expressed in this study are those of the investigators and do not necessarily reﬂect the views of
the funding agencies.
© 2010 by the American Diabetes Association. Readers may use this article as long as the work is properly
cited, the use is educational and not for proﬁt, and the work is not altered. See http://creativecommons.
org/licenses/by-nc-nd/3.0/ for details.
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby
marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Clinical Care/Education/Nutrition/Psychosocial Research
BRIEF REPORT
care.diabetesjournals.org DIABETES CARE, VOLUME 33, NUMBER 12, DECEMBER 2010 2549(1) were used to evaluate whether taking
ADMs was associated with developing
diabetes.
ADM use was deﬁned as a time-
dependent categorical variable up to each
time point evaluated with three levels:
never used, used intermittently (at least
once but not always), and used continu-
ously (at all visits). At each successive
time point, the value of the variable was
calculated based on all previous time
points, including the current measure-
ment. A signiﬁcant interaction between
ADM use and treatment groups was de-
tected, and we modeled the association
separately for each treatment group.
Time-dependent covariate analyses
(1) were used to model the above covari-
ates and diabetes risk with adjustment for
factors associated with an increased risk
of developing diabetes (race/ethnicity,
age, sex, education, fasting plasma glu-
cose at baseline, weight at baseline, and
weight change during the study). These
risks are reported as adjusted hazard ra-
tios (HRas).
We now present data over a median
of 10 years since randomization, includ-
ingthetimeperiodoftheﬁrstphaseofthe
DPP that was reported previously (1).
Therefore, these analyses are not inde-
pendentofthepreviousstudyandshould
be considered an extension, not a replica-
tion, of those ﬁndings. All analyses were
performed using SAS (SAS Institute,
Cary, NC).
RESULTS— When other factors asso-
ciated with an increased risk of develop-
ing diabetes were controlled, continuous
ADM use during the DPP/DPPOS (com-
pared with no use) was strongly associ-
ated with diabetes risk (Fig. 1) for
participants in the placebo (HRa 2.34
[95% CI 1.32–4.15] and lifestyle (2.48
[1.45–4.22]) arms. In the placebo arm,
the association between intermittent
ADM use and diabetes trended toward
statistical signiﬁcance (1.34 [0.99–
1.81]). In the metformin arm, ADM use
was not associated with diabetes risk
(0.55 [0.25–1.19]). There was a signiﬁ-
cant difference between the lifestyle and
metformin arms in the association be-
tween ADM and diabetes risk. Results did
not change when we excluded partici-
pants taking ADMs that are more likely to
cause weight gain (tricyclic and tetracy-
clic agents).
CONCLUSIONS — The current ﬁnd-
ings extend those of our earlier report (1),
althoughoverthelongerfollow-upinthis
study that includes the DPPOS, we did
not ﬁnd an association with intermittent
ADM use and diabetes risk in the lifestyle
arm.Theseﬁndingsaresimilartothosein
a previous report that long-term use of
ADM increased the risk of developing di-
abetes (4). Other studies (5,6), have also
reported increased ADM-related diabetes
risk.
The association between ADM use
and diabetes risk remained signiﬁcant
when likely mediators of this association
were controlled. This association could
represent a medication effect, or it could
reﬂect differences not assessed in the
studybetweenADMandnon-ADMusers.
ADMusewasnotassociatedwithdiabetes
riskinthemetforminarm.Althoughthere
is no obvious explanation for this latter
ﬁnding, one study found that metformin
induces the release of 5-hydroxytrypta-
mine through neuronal and nonneuronal
mechanisms and thus increases insulin
secretion (7). Metformin also appears to
ameliorate inﬂammation (8), and inﬂam-
matory markers appear to be associated
with depression (9).
Strengths and limitations
Strengths of the current study include the
large, racially and ethnically diverse pop-
ulation, the deﬁnitive assessment of glu-
cose tolerance and diabetes, repeated
collection of data on both ADM use and
depression symptoms, and repeated as-
sessment of metabolic diabetes risk fac-
tors.Wewerealsoabletomoreaccurately
determine the onset of diabetes—a con-
siderable advance over studies that rely
on clinical records that may not accu-
rately capture when diabetes actually
developed.
Potential DPP participants were ex-
cluded if they were taking bupropion or
any ADM in greater than the lowest ther-
apeutic dose, so the study sample was not
representative of the general population.
The absolute number of diabetes cases in
the continuous ADM group was quite
small (placebo n  18, lifestyle n  15).
DuringtheDPP/DPPOSwedidnotcollect
data on ADM dosage, so we could not
examine the association between dosage
and diabetes risk.
Implications
Further study of ADM-related diabetes
riskhassubstantialpublichealthimplica-
tions. The possible beneﬁts of metformin
in depression treatment should also be
studied.
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